Congresses and exhibitions 

View NMS presentations below.
Posters available upon request at the following address: lucia.reffo@nervianoms.com



2010

• September 29-October 2
  XXVIII Conferenza Nazionale di Citometria
  Urbino, IT
  Web link
  
  Oral presentation
  TBA
  P. Cappella
  
  
  
• September 12-16
  NMMC 2010 - XX National Meeting on Medicinal Chemistry
  Abano Terme, IT
  Web link
  
  Oral presentation
  TBA
  MG. Brasca
  
  Abstract
  TBA
  P.Orsini
  
  
  
• September 5-9
  XXIst International Symposium on Medicinal Chemistry
  Brussels, Belgium
  Web link
  
  Abstract
  TBA
  M. Menichincheri
  
  
  
• July 21
  Italian MRI/MRS Users' Meeting
  Torino, IT
  Web link
  
  Oral presentation
  "In vivo" homing of labelled neural stem cells in a mouse model of spinal cord injury
  A. Degrassi
  
  
  
• July 8-10
  Secondo Congresso Nazionale di Bioingegneria
  Torino, IT
  Web link
  
  Abstract 60
  Quantitative evaluation of the Aurora inhibitor effect on gene and protein expression: a mathematical modelling approach
  N. Terranova, R. Bosotti, Carpinelli P, G.Galli, M Bertolotti, P. Magni
  
  
  
• June, 21-23
  Next generation kinase inhibitors - Oncology and Beyond
  Cambridge, MA
  Web link
  
  Oral presentation
  Mitotic spindle kinase inhibitors to target aneuploid cancer cells.
  J. Moll
  
  Oral presentation
  New trends and opportunities in kinase inhibitors design.
  F. Zuccotto
  
  
  
• June, 8-9
  The 5th annual cell-based assays conference
  Cologne
  Web link
  
  Oral presentation
  Cell-based profiling and screening assays for protein kinases.
  F. Gasparri
  
  
  
• June 4-8
  ASCO
  Chicago, US
  Web link
  
  Abstract 2087
  Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).
  A. Benouaich-Amiel, E. Mazza, C. Massard, P. Gaviani, F. Fiorentini, A. Scaburri, M.A. Pacciarini, E. Calvo
  
  Abstract 3063
  Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.
  R. Bahleda, A. Spreafico, J. C. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri, M.A. Pacciarini, B. L'affranchi, M. Reni
  
  Abstract 3065
  Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.
  S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri, M. A. Pacciarini, R. Alzani, L. Gianni
  
  Abstract 3066
  Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
  P.J. Rosen, A.W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa, M.G. Jannuzzo, S. Comis, K. Papadopoulos
  
  Abstract 5014
  Phase II study of danusertib in advanced/ metastatic breast and ovarian cancers.
  C. Sessa, E. Gallerani, J.P. Delord, P. Schöffski, I. Vergote, V. Trillet-Lenoir, M. Maur, M.G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso
  
  
  
• May, 26-27
  Targeted Cancer Therapies
  London, EN
  Web link
  
  Oral presentation
  Cancer Cell Specificity for Cell Cycle Inhibitors - a Paradox or an Opportunity?
  J. Moll
  
  
  
• May, 16-20
  28th Camerino-Cyprus-Noordwijkerhout Symposium
  Camerino, IT
  Web link
  
  Oral presentation
  G protein coupled receptors: old landscape with new eyes.
  D. Donati
  
  
  
• April 17-21
  AACR
  Washington, US
  Web link
  
  Abstract 691
  In vitro and in vivo characterization of a selective orally available PARP-1 inhibitor with anti-tumor efficacy in BRCA negative cancer models.
  G. Papeo, S. Rainoldi, L.. Gianellini, A. Ciavolella, E. Corti, A. Leone, R. Lupi, F. Sola, F. Caprera, M. Paolucci, R. Perego, C. Albanese, E. Casale, B. Forte, M. Guanci, P. Orsini, H. Posteri, A. Scolaro, F. Riccardi-Sirtori, F. Zuccotto, D. Pezzetta, D. Donati, J. Moll, A. Montagnoli 
  
  Abstract 2522
  Identification and characterization of new highly selective and potent BRAF inhibitors.
  M. Pulici, N. Amboldi, S. Biondaro, F. Caprera, E. Casale, F. Gasparri, A. Leone, R. Lupi, C. Marchionni, M. Modugno, W. Pastori, G. Traquandi, F. Zuccotto, F. Colotta, D. Donati, E. R. Felder, A. Galvani, A. Isacchi, E. Pesenti, M. Ciomei
  
  Oral presentation
  NMS-1116354: more than an inhibitor of Cdc7 kinase in S-phase.
  F. Colotta
  
  
  
• March, 4-6
  TAT
  Bethesda, US
  Web link
  
  Oral presentation
  Danusertib, a pan-aurora kinase inhibitor: Clinical review.
  B. Laffranchi
  
  
  
• February 11-12
  Screening Europe
  Barcelona, SP
  Web link
  
  Oral presentation
  MPS-1 kinase inhibition in cancer cells: the fast track to cell death.
  J. Moll
  
  
  
• February 4-5
  Risonanza Magnetica in Medicina
  Milano, IT
  Web link
  
  Oral presentation
  MRI and PET evaluation of disease progression and efficacy of a cell cycle inhibitor on a lung adenocarcinoma transgenic mouse model.
  A. Degrassi
  
  
  

Archive 2009

Archive 2008

   VAT No. 04379750963

Credits     Terms of use